Filed with the Securities and Exchange Commission on November 19, 1998.
    

                           Registration No. 333-57173

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM S-3/A

   
                                 AMENDMENT NO. 5
    
             REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

                                  X-CEED, INC.
             (Exact name of registrant as specified in its charter)

                  488 Madison Avenue, New York, New York 10022
                                 (212) 753-5511
   (Address and telephone number of registrant's principal executive offices)

         Delaware                        3398                     13-3006788
(State or other jurisdiction     (Standard Industrial            (IRS Employer
       of incorporation)          Classification Code)            I.D. Number)


                      Werner Haase, Chief Executive Officer

                                  X-ceed, Inc.
                  488 Madison Avenue, New York, New York 10022
                                 (212) 753-5511
            (Name, address and telephone number of agent for service)


         Copies of all              Richard J. Blumberg, Esq.
         communications to:         McLaughlin & Stern, LLP
                                    260 Madison Avenue
                                    New York, New York  10016
                                    (212) 448-1100

         The registrant hereby amends this  registration  statement on such date
or dates as may be necessary to delay its  effective  date until the  registrant
shall file a further amendment which specifically  states that this registration
statement shall  thereafter  become effective in accordance with section 8(a) of
the  Securities  Act of 1933 or until the  registration  statement  shall become
effective on such date as the  Commission,  acting pursuant to section 8(a), may
determine.

         Approximate  date of commencement of proposed sale to the public:  from
time to time after the effective date of this Registration  Statement  depending
on market conditions.

         If the only securities  being registered on this Form are being offered
pursuant to dividend or interest  reinvestment plans, please check the following
box. [__]

     If any of the securities being registered on this Form are to be offered on
a delayed or continuous  basis  pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest
reinvestment plans, check the following box. [X]






         If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list  the  Securities  Act  registration  statement  number  of the  earlier
effective registration statement for the same offering. [__] ___

         If this  form is a  post-effective  amendment  filed  pursuant  to Rule
462(c) under the Securities Act, check the following box and list the Securities
Act  registration   statement  number  of  the  earlier  effective  registration
statement for the same offering. [__] ___



                         Calculation of Registration Fee


  Title of each class                                    Proposed            Proposed maximum
  of securities to be          Amount to be          maximum offering       aggregate offering           Amount of
      registered                registered            price per unit               price              registration fee

                                                                                                 
   Common Stock par           100,000 shares              $4.156                $415,600.00             $122.60 (1)
         value
    $.01 per share

<FN>
         (1)  Estimated  for purposes of this filing  pursuant to Rule 457(c) at
$4.156 per share  based upon the  average of the bid and asked  prices of $4.125
and $4.187, respectively, on June 16, 1998.
</FN>








PROSPECTUS


                                  X-CEED, INC.

            100,000 Shares of Common Stock, Par Value $.01 per Share.


                  This  Prospectus  relates to 100,000 shares of Common Stock of
X-ceed, Inc. (the "Company"), par value $.01 per share (the "Shares"), which may
be  offered  from  time  to  time  by the  Selling  Shareholders.  See  "Selling
Shareholders."  This  Prospectus  does not relate to the sale or issuance by the
Company of any securities.  Any Securities which are offered will be offered for
the account of the Selling  Shareholders,  who will acquire the securities  upon
the exercise of options which are owned by the Selling Shareholders. The Company
will  receive the proceeds  from the exercise of options  payable by the Selling
Shareholders upon the exercise of options. However, the Company will not receive
any proceeds from the sale of the  Securities by the Selling  Shareholders.  The
Company  has  been  advised  by  the  Selling  Shareholders  that  there  are no
underwriting  arrangements  with  respect  to the sale of the  Shares,  that the
Shares will be sold by the Selling  Shareholders from time to time on the NASDAQ
SmallCap  Market at the then  prevailing  price and in private  transactions  at
negotiated  prices and that usual and customary  brokerage fees, if any, will be
paid by the Selling Shareholders in connection therewith.

                  The  Company's  Common Stock is traded on the NASDAQ  SmallCap
Market under the symbol  "XCED." The closing bid  quotation for the Common Stock
was $4.125 on June 16, 1998.

                             ----------------------

                  AN INVESTMENT IN THESE SECURITIES INVOLVES A

        HIGH DEGREE OF RISK. (See "Risk Factors " commencing on page 9.)

                             ----------------------


THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE
SECURITIES AND EXCHANGE COMMISSION, NOR HAS THE COMMISSION PASSED
UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION
TO THE CONTRARY IS A CRIMINAL OFFENSE.


                 The date of this Prospectus is _________, 1998.


                                        2





                              AVAILABLE INFORMATION

                  The Company is subject to the  reporting  requirements  of the
Securities  Exchange Act of 1934 and in accordance  therewith  files reports and
information with the securities and exchange Commission (the "Commission"). Such
reports may be inspected at the public reference facilities at the Commission at
Judicial  Plaza,  450 Fifth  Street,  N.W.,  Washington,  D.C.  20549 and at the
following  regional  offices of the  Commission:  Suite 1400,  500 West  Madison
Street, Chicago, Illinois 60661-2511;  Seven World Trade Center, 13th Floor, New
York,  NY 10048;  Suite 500, 5757 Wilshire  Boulevard,  Los Angeles,  California
90036-3648.  Copies of such material may be obtained  from the Public  Reference
Section of the Commission, Washington, D.C. 20549, at prescribed dates.
                                -----------------

                  The Company  has  continued  and will  continue to furnish its
security holders with annual reports containing audited financial  statements at
the end of each fiscal year.  In addition,  the Company may,  from time to time,
issue unaudited interim reports and financial statements.

THE FOLLOWING LEGEND WILL APPEAR IN RED INK ON THE FRONT PAGE OF THIS
PROSPECTUS IN THE EVENT THAT THE PROSPECTUS IS CIRCULATED PRIOR TO
BEING DECLARED EFFECTIVE BY THE COMMISSION:

         "The   information   contained  herein  is  subject  to  completion  or
         amendment.  A registration  statement  relating to these securities has
         been  filed  with  the  Securities  and  Exchange   Commission.   These
         securities  may not be sold nor may offers to buy be accepted  prior to
         the time the registration statement becomes effective.  This prospectus
         shall not constitute an offer to sell nor the solicitation of any offer
         to buy, nor shall there be any sale of these securities in any state in
         which such  offers,  solicitation  or sale would be  unlawful  prior to
         registration or qualification under the laws of any such state."

                  The  Company  has filed  with the  Commission  a  Registration
Statement on Form S-3 (the "Registration Statement") under the Securities Act of
1933 relating to the securities offered hereby. This Prospectus is filed as part
of the  Registration  Statement and does not contain all of the  information set
forth in the Registration Statement, certain parts of which have been omitted in
accordance  with the rules and  regulations  of the  Commission.  Any statements
contained  herein  concerning the provisions of any document are not necessarily
complete, and, in each instance,  reference is made to the copy of such document
filed as an exhibit to the  Registration  Statement or otherwise  filed with the
Commission.  Each such statement is qualified in its entirety by such reference.
For further  information with respect to the Company and the securities  offered
hereby, reference is made to the Registration Statement,  including the exhibits
filed as a part thereof and other documents  incorporated  therein by reference.
Copies of the  Registration  Statement and the exhibits thereto may be inspected
and copied, at prescribed rates, at the public reference  facilities  maintained
by the Commission at the addresses set forth above.


                                        3





                           FORWARD-LOOKING STATEMENTS

                  All  statements  other  than  statements  of  historical  fact
included in this Prospectus regarding the Company's financial position, business
strategy  and plans and  objectives  of  management  of the  Company  for future
operations, are forward-looking statements. When used in this Prospectus,  words
such as  "anticipate,"  "believe,"  "estimate,"  "expect,"  "intend" and similar
expressions,  as  they  relate  to  the  Company  or  its  management,  identify
forward-looking  statements.  Such  forward-looking  statements are based on the
beliefs  of the  Company's  management,  as  well  as  assumptions  made  by and
information  currently  available to the Company's  management.  Actual  results
could  differ  materially  from  those   contemplated  by  the   forward-looking
statements as a result of certain  factors such as those  disclosed  under "Risk
Factors,"  including  but  not  limited  to,  competitive  factors  and  pricing
pressures,  loss of  major  customers,  technological  change  or  difficulties,
product development risks,  commercialization and trade difficulties and general
economic  conditions.  Such statements  reflect the current views of the Company
with  respect  to future  events  and are  subject  to these  and  other  risks,
uncertainties and assumptions relating to the operations, results of operations,
growth  strategy and liquidity of the Company.  All subsequent  written and oral
forward-looking  statements  attributable  to the  Company or persons  acting on
behalf are expressly qualified in their entirety by this paragraph.

                               PROSPECTUS SUMMARY

                  The  following  summary  information  does not  purport  to be
complete and is  qualified  in its  entirety by  reference to the more  detailed
information and financial  statements  appearing elsewhere in this Prospectus or
in documents  incorporated by reference.  Each prospective  investor is urged to
read this Prospectus in its entirety.

                                   THE COMPANY

                  The  Company  was  originally   incorporated  under  the  name
Trilling Resources,  Ltd. It changed its name to Trilling Medical  Technologies,
Inc. in September 1987 and subsequently to Water-Jel Technologies,  Inc. in July
1991. On February 20, 1998,  shareholders approved a name change to X-ceed, Inc.
and also approved a change in the Company's state of incorporation from New York
to Delaware.  The Company's executive offices are located at 488 Madison Avenue,
New York, NY 10022 and its telephone number is (212) 753-5511.

                  Since the inception of the Company until 1996, the Company was
primarily  engaged in the  development,  manufacture  and marketing of emergency
first  aid  products  for  industry  and on a  limited  basis  for the  consumer
marketplace.

                  In July 1996,  the  Company  acquired  all of the  outstanding
stock of  Journeycraft,  Inc., a company engaged through its X-ceed  Performance
Group division in providing services to corporations in the field of performance
improvement and corporate  communications  and through its  Journeycraft  Travel
Management  division in providing travel  management to corporate  clients.  The
Company  also  acquired  all of the  outstanding  stock of  TheraCom  Integrated
Medical  Communications,  Inc.  ("TheraCom"),  which is engaged in training  and
communications in the health

                                        4





care  industry  as well as the  marketing  of  innovative  products  for patient
education, especially in the women's health care field.

                  As the Company is presently  constituted,  the Water-Jel First
Aid division  manufactures  and markets a proprietary line of first aid products
for burns and a line of generic creams and ointments.  The  proprietary  line of
first aid products  for burns  consists of fire  blankets,  burn  dressings  and
topical  creams  which are marketed to the  industrial  as well as, on a limited
basis,  the consumer  marketplaces.  The division's  generic creams and ointment
product line consists of hydrocortisone cream, triple antibiotic ointment, first
aid cream,  antiseptic  gel and a hand and body lotion which are marketed  under
the WJ brand. The division also provides private label packing of its creams and
ointment products to some of its customers. For the fiscal year ended August 31,
1997, the Water-Jel  division's  revenues  accounted for approximately 8% of the
Company's total revenues.

                  The X-ceed  Performance  Group  ("X-ceed  Performance  Group")
assists corporate clients in establishing  performance improvement programs such
as sales programs and other marketing and promotional performance programs. This
division  derives  its  revenues  from  service  fees  charged  the  client  for
establishing  a  performance  improvement  program and fees for  monitoring  the
programs,  as well as  mark-ups  on the  services  and  merchandise  provided as
awards.  For the fiscal year ended August 31,  1997,  X-ceed  Performance  Group
accounted for approximately  59% of the Company's total revenues.  Approximately
66% of the  revenues  were  derived  from  two  clients,  Pfizer,  Inc.  and MCI
Communications,  Inc. A loss of either of these clients' business or a reduction
in fees could have a material  effect on the  Company's  revenues in the future.
See "Risk Factors."

                  The  Journeycorp   division  provides   comprehensive   travel
services   primarily  for  business   travel,   which  includes  trip  planning,
reservations,  ticketing and other incidental services.  This division also acts
as a consultant  regarding  corporate travel policies and travel budgeting.  The
division  derives its revenues from fees and  commissions  generated from travel
bookings  and from hotels,  car rental  companies  and other  travel  suppliers.
Revenues  are also  derived  from  travel  consulting  fees  charged to selected
accounts. At the present time, the airlines are shifting away from paying travel
agents  fees,  and as a  result,  this  division  is  reorienting  its  customer
relationships  towards  fee-based travel  management.  However,  there can be no
assurance  that the division will be successful.  (See "Risk  Factors.") For the
fiscal year ended August 31, 1997,  Journeycorp  accounted for approximately 17%
of the Company's total revenues.


                  The TheraCom  Communications  subsidiary  provides  integrated
training,  communication  and data to the healthcare  industry.  In this regard,
TheraCom  provides all services  necessary to organize  meetings to assist major
pharmaceutical  companies in  providing  healthcare  professionals  with current
medical information. TheraCom locates speakers and provides publicity and travel
arrangements.  In addition,  TheraCom has  expanded  its  operations  to include
direct patient education by pharmaceutical  companies. For the year ended August
31, 1997, TheraCom's revenues accounted for approximately 14.5% of the Company's
total revenues. These revenues were primarily derived from one customer, Pfizer,
Inc. ("Pfizer").  A loss of Pfizer or a reduction in services required by Pfizer
could have a material effect on the Company. (See "Risk Factors.")


                                        5






                               RECENT DEVELOPMENTS

                  During the third  quarter of the  Company's  fiscal year,  the
Company's management made a decision to make strategic  acquisitions designed to
enable the  Company to operate as an  integrated  marketing  and  communications
company with interactive and Internet services at its core.


                  The first of the  acquisitions  occurred  on August 29,  1998,
when the Company,  through a newly established subsidiary,  X-ceed Acquisitions,
Inc.  ("Acquisitions"),  acquired  all of the  issued and  outstanding  stock of
Reset,  Inc., a privately  held company  established  in 1997 and engaged in the
business  of  offering  interactive  marketing  strategies  to its  clients  and
creating  website  design,   website  database   software,   Internet   commerce
development,  DHTML streaming video and CD-ROM design. The consideration for the
transaction was the issuance of "restricted" X-ceed Common Stock having a market
value of $6,250,000 in exchange for all of the issued and outstanding  shares of
Reset. Upon the completion of the transaction,  Acquisitions changed its name to
Reset  and Reset now  operates  as a  wholly-owned  subsidiary  of the  company.

     At the  present  time,  approximately  seventy  percent  (70%)  of  Reset's
business is with the  entertainment  industry.  Its current clients are Home Box
Office,  Interscope  Records,  Warner Bros. and  Bertelsmann  Music Group,  Inc.
("BMG" -- RCA, Arista and Jive Records).  Its other current clients are The Wall
Street Journal,  Consolidated Edison, Inc.,  Britt-Allcraft Co. Ltd. and Quantum
Motorcycles.  One client, Home Box Office,  presently accounts for approximately
fifteen percent (15%) of Reset's total revenues.


                  On September 9, 1998, the Company completed the acquisition of
Mercury Seven,  Inc.  ("Mercury Seven") by way of merger of Mercury Seven into a
newly  created  subsidiary  of  the  Company,  X-ceed  Merger,  Inc.  After  the
completion of the Merger, X-ceed Merger, Inc. changed its name to Mercury Seven,
Inc. The Company paid a total  consideration  consisting of 1,073,333  shares of
"restricted"  X-ceed  Common Stock and a cash  consideration  of  $1,500,000  in
exchange for all of the issued and outstanding stock of Mercury Seven.

                  Mercury Seven, a privately  held company,  was  established in
late 1996. The company is a consultancy and development company that specializes
in advising  and  assisting  clients in building and  developing  Internet-based
businesses.  Mercury Seven is also the creator and publisher of ChannelSeven.com
("ChannelSeven")  an online network for Internet  professionals  worldwide.  The
network  incorporates  cross-marketing  navigational  techniques and centralized
rich-media   advertising  management  to  connect  Internet  professionals  with
valuable resources and services. In addition to the online network, ChannelSeven
provides its core audience with printed publications, special industry events, a
speaker's  bureau  and a  subscription  based  E-mail  newsletter.  ChannelSeven
derives its revenues from advertising and sponsorship.


                  At the present time,  Mercury  Seven's current clients include
Spree.com,  WorldNow/Gannaway,  AnotherUniverse.com,  Men's Health, the New York
Rangers,  WinFreeMoney.com  and Madison  Square  Garden.  


                                        6






At the present time,  Spree.com,  Men's Health and WinFreeMoney.com each account
for  approximately  ten percent  (10%) of Mercury  Seven's  total  revenues.  In
addition,  the  current  advertisers  and  sponsors of  ChannelSeven  are Intel,
Microsoft, DoubleClick, Ericsson and Cyberlab, Inc.


     On September 14, 1998 the Company completed a Plan of Merger with Zabit and
Associates,  Inc. ("Zabit"),  a privately owned corporation engaged in corporate
communications.  In exchange for all of the issued and outstanding  Zabit common
stock, the Company paid a total consideration which consisted of the issuance of
2,258,724  shares of  "restricted"  X-ceed Common Stock and the issuance of four
notes totaling  $6,670,208.  Two of the notes for $4.8 million are payable on or
before March 15, 1999 and two of the notes for  $1,930,208  are due on or before
September 14, 2002.  All of the notes bear interest.  In separate  transactions,
the Company  purchased all of the issued and  outstanding  Common Stock of Water
Street Design Group,  Inc., a company engaged in design and production and owned
by the  principals  of Zabit for $2 million and the trade name and  trademark of
Zabit for $3.2 million in cash.


     Zabit was formed in 1993 and since that time has been  engaged in  advising
organizations,  primarily  publicly  held  companies,  in  solutions  for  their
communication  problems in connection with the  dissemination  of information to
employees,  shareholders,  customers  and the public.  The Company  maintains an
ongoing relationship with UEC Corporation,  Silicon Graphics,  Inc.,  Starbucks,
Anthem  Health  Care,  Kaiser  Permanente,  Ernst &  Young  and  Fireman's  Fund
Insurance  Company.  Each of these  clients has paid in excess of  $200,000  for
Zabit's services.  In addition,  Zabit has other ongoing clients, such as Pitney
Bowes,  Shell/Texaco,  McKesson Corp., and Indiana Power and Light, from each of
whom  Zabit has  received  to date fees of less than  $200,000.  Fireman's  Fund
Insurance Company presently accounts for approximately  fifteen percent (15%) of
Zabit's total revenues.

                  Additionally and as part of the Zabit transaction, the Company
entered into an employment  agreement with William Zabit, the principal owner of
Zabit, making him President of X-ceed. His employment  agreement is for a period
of four years and provides for an annual salary of $400,000,  with the potential
for bonuses based upon performance and profitability of the Company.

                  All of the three  transactions will be accounted for under the
purchase  method of  accounting.  The Company  estimates that as a result of the
three  transactions,  the Company will report on its financial  statements  good
will and other intangibles of approximately $41 million.


                  As part of the  Company's  new  objectives  to  operate  as an
integrated marketing and communications company, the Company has entered into an
employment  agreement  with Scott  Mednick,  who has  assumed  the  position  of
Co-Chairman  of the Board of  Directors  along  with  Werner  Haase as the other
Co-Chairman.  Mr.  Mednick  has  also  assumed  the  responsibilities  of  Chief
Strategic Officer of the Company.

                  Mr.  Mednick  was the  founder  and past  chairman  and  chief
executive  officer  of THINK New  Ideas,  Inc.  ("THINK").  Under Mr.  Mednick's
direction,  THINK was named as one of the top  interactive  agencies of the year
(1995) by both Adweek and the Advertising Club of New York. Mr. Mednick enjoys a
reputation as a highly respected marketing strategist and graphic designer.


                  Mr.  Mednick's  employment  agreement  is for a period of four
years at an annual  salary of $350,000 per year,  together with bonuses based on
the Company's performance and profitability. In addition, Mr. Mednick received a
signing bonus of $960,000 payable in twelve monthly  installments and options to
purchase  1,000,000 shares of the Company's Common Stock at an exercise price of
$6.00 per share.  However, of the 1,000,000 shares,  500,000 may only be sold in
increments  of 100,000  shares when the market price of the Common Stock attains
certain price levels, ranging from $12.00 a share to $24.00 a share.


                             SELECTED FINANCIAL DATA

                  The selected  financial data presented below for the Company's
statements of operations for the years ended August 31, 1995,  1996 and 1997 and
the  balance  sheet  data at  August  31,  1996 and 1997  are  derived  from the
Company's  financial  statements  which have been audited by Holtz  Rubenstein &
Co.,  LLP,  independent  public  accountants,  and  which  are  incorporated  by
reference.  The statement of operations  data for the year ended August 31, 1994
and


                                        7






the  balance  sheet data at August 31, 1994 and 1995 are  derived  from  audited
financial  statements of the Company which are not included in this Registration
Statement.  The statement of  operations  data for the nine months ended May 31,
1997  and 1998 and the  balance  sheet  data at May 31,  1998 are  derived  from
unaudited financial  statements which are incorporated by reference.  Management
believes that all adjustments  necessary for a fair  presentation have been made
in such interim periods.  However, the results of operations for the most recent
interim period are not necessarily indicative of the Company's financial results
for the entire current fiscal year.


Statement of Operations Data




                                                   Year Ended August 31,                            Nine Months Ended May 31,
                               ------------------------------------------------------------      -------------------------------
                                  1994             1995             1996             1997             1997             1998
                                  ----             ----             ----             ----             ----             ----
                                                                                                          
Net sales                    $41,332,876       $43,515,440      $54,863,574      $62,885,464      $45,406,465       $44,347,737

Operating income (loss)         (301,947)        2,770,259        1,219,044        3,924,206        3,071,031         2,016,728

Net income                     1,353,264         2,131,242          632,315        1,876,620        1,624,851         1,288,998

Net income per
  common share (1)
   -Basic                            $.20             $.30             $.09             $.27             $.23              $.18
   -Diluted                          $.20             $.30             $.09             $.26             $.22              $.16

 Weighted average
  number of shares
   outstanding (1)
   -Basic                       6,738,327        6,999,180        7,001,295        7,023,770        7,021,145         7,279,691
   -Diluted                     6,790,310        7,079,388        7,394,012        7,339,625        7,256,262         7,865,096

Balance Sheet Data

Working capital              $  3,854,425    $  5,119,676     $  7,964,147      $10,042,076      $  8,750,912       $16,141,855

Total assets                   13,142,536      17,474,716       17,383,178       18,800,080        22,498,212        33,124,330

Long-term debt                     17,744         129,900           90,700           51,500            61,300            22,100

Cash dividends                       -                -                -                -                -                 -

<FN>
- ---------------------------
         (1) Net income per common share and weighted  average  number of shares
outstanding data for periods prior to December 31, 1997 have been  retroactively
restated to reflect  computation  under  Financial  Accounting  Standards  Board
Statement No. 128 "Earnings Per Share".
</FN>




                                  THE OFFERING

Common Stock -                         100,000  shares  of Common  Stock
                                       underlying   100,000  options  previously
                                       granted to the Selling Shareholders.  The
                                       options  permit  the  holder  thereof  to
                                       purchase  one share of  Common  Stock for
                                       each option at an exercise price of $1.52
                                       per share.

                                        8




                                       All expenses relating to the registration
                                       of   these   securities,   estimated   at
                                       $18,000, will be borne by the Company.

Use of Proceeds -                      The  Company   will  not
                                       receive any proceeds from the sale of the
                                       securities.   The  Company  will  receive
                                       $152,000,     assuming     the    Selling
                                       Shareholders  elect  to  exercise  all of
                                       their options.

                                  RISK FACTORS

                  Purchase  of the  securities  offered  hereby  involves a high
degree of risk and  prospective  purchasers  should  consider the following Risk
Factors as well as the other  information  contained in this  Prospectus and the
exhibits attached to the Registration Statement as well as Exhibits incorporated
by reference herein.

Competition

                  In July 1996,  the  Company  acquired  all of the  outstanding
stock of Journeycraft and TheraCom. These businesses have significantly expanded
the Company's operations.  However, the various products and services offered by
these  subsidiaries and divisions face intense  competition.  The following is a
discussion of the competitive factors that each division or subsidiary presently
faces.

                  The  Water-Jel  division  manufactures  and  markets a line of
first aid products for burns and a line of generic creams and  ointments.  There
are other  companies,  such as Spenco Medical  Corporation,  C.R. Bard, Inc. and
Johnson & Johnson, which manufacture similar first aid products for burns. These
companies  have  been  established  for a  longer  period  of time,  are  better
established and have financial  resources and facilities  which are greater than
the  division's.  While some segments of the burn first aid market are dominated
by large  manufacturers,  other  segments  of the  market are  characterized  by
intense competition among smaller manufacturers such as Water-Jel.

                  The  X-ceed   Performance   Group   division,   which   offers
performance improvement and motivational programs to corporate clients, is faced
with intense competition from several well-established companies, such as Maritz
Inc.,  Carlson  Marketing Group,  Inc. and B.I.  Performance  Group,  Inc. These
companies are well  established  and have greater name  recognition  than X-ceed
Performance  Group.  Likewise,  they  generate  revenues far in excess of X-ceed
Performance  Group's.  They also have a much broader customer base. In addition,
X-ceed Performance Group competes with numerous smaller consultants and likewise
has  to  compete  with  corporations'  in-house  staff  who  devise  performance
improvement and motivational programs.  Only recently,  X-ceed Performance Group
introduced  "Maestro," a proprietary  Inter- and Intranet software program to be
used in conjunction with X-ceed Performance Group's performance programs.  While
the Company believes this software is unique,  competitors could introduce their
own software programs to monitor  performance  improvement  programs and compete
for business.

                  The Journeycorp division,  which provides comprehensive travel
services for business travel,  faces intense  competition,  since there are more
than 30,000 travel agents in the United States

                                        9





which are capable of providing  business travel services.  Journeycorp must also
compete with in-house travel departments and those airlines which require direct
booking with the airline.

                  The TheraCom  subsidiary,  which provides integrated training,
communications  and  data  to  the  healthcare  industry,   competes  with  many
consultants who provide similar  services to the healthcare  industry.  TheraCom
competes on the basis of price and quality of its  services.  To date,  TheraCom
has only one  significant  customer,  Pfizer,  Inc.  TheraCom is  attempting  to
broaden its client base,  and no assurances  can be made that it will be able to
effectively compete.


                  The Mercury  Seven  subsidiary  and Reset  subsidiary  provide
services in a highly competitive market. These two subsidiaries face competition
from a number of  sources,  including  national  and  regional  media  marketing
companies,  as well as local  advertising  agencies  which have begun to develop
interactive media capabilities.  Many of Mercury Seven's and Reset's competitors
have  longer  operating  histories,  longer  client  relationships  and  greater
financial and technological  resources than either Mercury Seven or Reset. There
can be no  assurance  that  existing or future  competitors  will not develop or
offer  marketing  communication  services and products that provide  significant
performance, creative or other advantages, including pricing, over those offered
by either Reset or Mercury Seven,  which could have a material adverse effect on
the financial condition and operating results of the Company.

                  The Zabit division competes with several companies,  including
Arthur Anderson Consulting,  Towers and Perrin,  William M. Mercer & Company and
Watson  Wyatt  Worldwide.  Zabit's  competitors  for the most part  have  longer
operating histories,  longer client  relationships,  greater financial resources
and greater  technological  resources  than Zabit.  While Zabit  believes it can
effectively  compete and has within the last five years  developed a significant
client  base,  there can be no  assurances  that  Zabit will be able to keep the
present  client  base  or  attract  new  clients.  In  the  event  Zabit  cannot
effectively  compete,  this  could  have a  material  effect  on  the  financial
condition and operating results of the Company.  

Market and Technological Change Affecting Journeycorp and X-ceed Performance 
Group

                  Several of the  markets in which the  Company's  products  and
services are offered are undergoing technological advances and other changes. In
particular,  and with  respect to  Journeycorp,  the  airlines  have lowered the
commissions  they are willing to pay travel agents.  As a result,  the corporate
travel  business is changing  from  commission  to  fee-based  services in which
corporate  travel service  providers such as Journeycorp  are paid fixed fees by
their clients in lieu of  commissions  based upon the volume of travel  services
purchased.  These  developments have tended to reduce the revenues  available to
travel  service  providers  such as  Journeycorp.  Also,  the  corporate  travel
business is experiencing  technological  changes such as "ticketless" air travel
and  Internet-based  reservation  systems  which  tends to  reduce  the need for
outside  travel  agents.  These changes are further  accelerating  the trend for
travel service  businesses to act as  consultants  working for fixed fees rather
than commission-based  booking agencies.  With respect to the X-ceed Performance
Group division,  a significant amount of X-ceed Performance  Group's business is
based upon the development of innovative  technologies for delivering  incentive
programs   using  the  Internet.   The  Internet  is   characterized   by  rapid
technological advances which may render X-ceed


                                       10





Performance Group's technologies  out-of-date or obsolete. There is no assurance
that  X-ceed  Performance  Group  will  be  in  a  position  to  adapt  to  such
technological advances and market changes.


Risks of Integration

                  In light of the  recent  acquisitions  of Reset,  Mercury  and
Zabit,  the  Company's  success will depend in part on its ability to manage the
combined  operations of those companies and to integrate the operations of these
companies  along  with  its  other  subsidiaries  and  divisions  into a  single
organizational  structure.  There can be no  assurance  that the Company will be
able to effectively  integrate the operations of its  subsidiaries and divisions
into a single  organizational  structure.  Integration of these operations could
also place  additional  pressures on  management as well as on the key technical
resources of the Company.  The failure to successfully  manage this  integration
could have a material effect on the Company.  Finally,  while it is management's
belief  that the newly  acquired  entities  can  market  these  services  to the
Company's  existing clients as well as to existing clients of the newly acquired
companies,  there can be no assurance that the cross-marketing  will be achieved
or sustained. 

Future Capital Requirements

                  The  acquisitions of Mercury and Zabit required the Company at
closing to pay cash as part of the  consideration:  $1.5  million in the case of
Mercury  and $5.2  million  in the case of  Zabit.  The Zabit  transaction  also
requires  the Company to pay an  additional  $4.8 million in March 1999 and $1.9
million on or before  September  14, 2002,  together  with  interest.  While the
Company  believes that its present cash  position and cash flow from  operations
will be sufficient to fund its  operations,  the Company may require  additional
financing to sustain  further  growth and expand its  business.  There can be no
assurance  that the Company  will be able to  successfully  negotiate  or obtain
additional  financing  or that  such  financing  will be on terms  favorable  or
acceptable to the Company.  The failure to secure necessary financing could have
a  material  adverse  impact  on  the  Company.  

Dependence  on  the  Internet's Developing Market

                  The Company's  ability  primarily through Reset and Mercury to
derive revenues by providing marketing solutions through the use of the Internet
will depend in part upon a robust industry and the  infrastructure for providing
Internet access and the management of Internet  traffic.  While the Internet has
made significant  improvements in both accessing and managing traffic, there can
be no  assurance  that as more  demand is made upon the  Internet  technological
improvements will keep pace. Additionally, critical issues concerning the use of
the Internet, including security,  reliability, cost, ease of use and access and
quality of service still remain to be resolved,  and as such the Internet  could
prove  not  to be a  commercially  viable  marketplace.  This  could  result  in
impacting the Company's future operating results.


                                       11






Rapid Technological Changes in Interactive Marketing Services  

                  The  market for such  interactive  marketing  services  as the
Company   provides   though  its  Reset  and  Mercury  Seven   subsidiaries   is
characterized  by rapid  changes  in  technology.  As such it will  require  the
Company to maintain its technical  competence to effectively  compete with other
integrated  marketing  service  providers  as  well as  traditional  advertising
agencies.  There can be no  assurance  that the Company  will be  successful  in
providing competitive solutions to its clients. Failure to do so could result in
the loss of  existing  customers  or the  inability  to  attract  and retain new
customers,  and as a result,  this could have a material  adverse  effect on the
business,  financial  condition  and operating  results of the Company.

Project Profit Exposures; Need to Develop Recurring Revenue

                  Zabit, Mercury Seven and Reset normally generate a substantial
majority of their revenue through project fees on fixed  fee-for-service  basis.
Zabit, Mercury Seven and Reset assume greater financial risk on fixed-price type
contracts  than on either  time- and  material- or  cost-reimbursable  contract.
Failure to anticipate  technical problems,  estimate costs accurately or control
costs during  performance  of a fixed-price  contract may reduce Zabit,  Mercury
Seven  and  Reset's  profit or cause a loss.  Although  the  majority  of Zabit,
Mercury  Seven and  Reset's  projects  typically  last six to  twelve  weeks and
therefore  each  individual  short-term  project  creates less  exposure  than a
long-term  fixed-price  contract, in the event Zabit, Mercury Seven and Reset do
not   accurately   anticipate   the   progress   of  a  number  of   significant
revenue-generating  projects,  it could have a material adverse effect on Zabit,
Mercury Seven and Reset's operating  results.  Zabit,  Mercury Seven and Reset's
future   success  will  depend  in  part  on  their  ability  to  convert  their
project-by-project  relationships to continuing  relationships  characterized by
recurring  revenue.  There can be no  assurance  that Zabit,  Mercury  Seven and
Reset's efforts will be successful. 

Dependence on Few Customers

                  At the present time,  approximately 80% of TheraCom's services
are supplied to one  customer,  Pfizer,  Inc.  ("Pfizer").  Of the revenues from
X-ceed Performance Group's business,  for the fiscal year ended August 31, 1997,
66% was derived from two clients,  Pfizer and MCI  Communications,  Inc.,  which
represent  35% of  revenues  and 31% of  X-ceed  Performance  Group's  revenues,
respectively.  The loss of either of these  clients or a reduction in the amount
of business  generated from these two clients could materially  adversely affect
the Company's future business and prospects.

No Contracts with Customers

                  With few  exceptions,  the  Company  does not have any written
agreements  with its customers or clients,  or such agreements are terminable at
will upon relatively short notice.  Unexpected or other termination of relations
with  significant  customers could adversely  affect the Company's  business and
prospects. See "Competition" and "Dependence on Few Customers."


                                       12





Fluctuations in Revenues

                  For the six months ended  February 28, 1998  ("Fiscal  1998"),
the Company's revenues declined by approximately $5,600,000 as compared with the
revenues for the six-month  period ended  February 28, 1997 ("Fiscal  1997").  A
major portions of this decline was due to a refinement of revenue recognition by
the  TheraCom  subsidiary.  In 1997,  the  Company's  TheraCom  division,  which
provides  integrated  training,  communication  and  data  to  the  health  care
industry,  refined its method of revenue recognition.  Previously,  the division
recognized the revenues  generated from its calendar year programs at the end of
the program. In 1997, based upon its improved accounting information systems and
controls,  it was determined  that the division  recognize  revenue and costs on
certain calendar year programs ratably as certain performance criteria occurred.
Revenues recorded by TheraCom approximated $4,187,000 and $5,717,000 for the six
months  ended  February  28,  1998 and 1997,  respectively.  The  decline in the
Company's  revenues for the six months  ended  February 28, 1997 was also due in
part to the  types of award  programs  required  by the  clients  of the  X-ceed
Performance  Group  division.  Because that  division is primarily  dependent on
business from two major clients, any curtailment or change in the award programs
can result in material  fluctuations during quarterly periods.  Investors should
therefore be cautioned  that because of the  dependence  on a limited  number of
clients, the Company may experience fluctuating revenues and earnings in varying
periods. 

Market Acceptance for Company's Products and Services

                  The Company  believes  that its ability to market its products
and  services  requires  educating  potential  users  as to their  benefits  and
applications.  This is particularly true for the Internet technologies developed
by  X-ceed   Performance  Group  and  the  first  aid  product  line  for  burns
manufactured  by the  Water-Jel  division.  No  assurance  can be given that the
Company  will be able to  successfully  increase the market for its products and
services.


                                       13





Limited Patents and Proprietary Information

                  The  X-ceed   Performance   Group  division  has  developed  a
proprietary  software,  "Maestro,"  which is designed to enable clients to trace
the progress of sales promotion  programs and other types of award programs over
the  Internet.  The  clients  who elect to utilize  Maestro do not  receive  the
software,  but rather are only granted a license to utilize the software,  which
is  at  all  times  maintained  at  the  Company's  offices.  The  clients  feed
information  to the  "Maestro"  program  over the  Internet  by using a  sign-on
identification  and password.  The clients can  thereafter  gain access with the
proper  password  to Maestro to enable them to  evaluate  the  progress of their
awards  program.  The Company does not presently hold a copyright to the Maestro
software  but  intends  to apply  with the US Patent  and  Trademark  office for
protection as well as a trademark on the name  "Maestro." The actual software is
retained under stringent  controls at the Company's offices and only four people
within the  Company  and under  confidentiality  agreements  have  access to the
software and code.  Should the Company's  Maestro software and other proprietary
technology  be disclosed  publicly,  the  business  and  prospects of the X-ceed
Performance Group could be adversely affected. Likewise, and if there was public
disclosure  of the software and codes,  the Company at the present time may have
no or very limited legal recourse, unless the Company could demonstrate that the
codes  and  software  were  illegally  converted  or taken  or that the  clients
violated their licence agreements with the Company.

                  The design of Water-Jel's  Fire Blanket products was protected
by United States and foreign  patents which were assigned to the Company in 1979
and 1985. The United States patent which protected a substantial  portion of the
Company's  technology  expired  in  1992.  New  competitors  may now  enter  the
Company's  markets.  The Company may be materially and adversely affected if the
Company  should fail to  establish a secure  market base before the  entrance of
significant  new  competitors  now that the original  United  States  patent has
expired.  See "Competition."  Further, in January 1995,  Water-Jel was granted a
patent for a synthetic fabric containing a therapeutic, non-toxic, water-soluble
and  bio-degradable  gel used in the Company's Burn Dressing  product line. This
patent  expires in April  2014.  However,  no  assurance  can be given that this
patent will prove enforceable or prevent others from marketing  products similar
to, or which perform  comparable  functions  as, the  Company's  products at the
current  time,  the  Water-Jel  burn  dressing  products  covered by this patent
account for  approximately  thirty percent (30%) of Water-Jel's  revenues.  

Year 2000 Compliance

                  The  Company  has  taken  remedial  steps to  ensure  that its
computer systems are compliant with the Year 2000 ("Y2K").  In this regard,  the
X-ceed  Performance  Group has  purchased for internal  operations  new personal
computers  (PCs)  which  have  been  tested  by the  National  Software  Testing
Laboratories  (NSTL) and have been certified as Y2K  compliant.  With respect to
client  support,  the division has upgraded its software at no extra cost and is
compliant with Y2K. With respect to the Company's  internal  software  affecting
accounting systems and telecommunications, the Company estimates that it will be
required to purchase  additional  equipment  for $15,000 in order to achieve Y2K
compliance in this area.  With respect to the Journeycorp  division  reservation
systems, the division utilizes PC hardware provided by the Sabre

                                       14





Group, the American Airlines  reservations  system.  American Airlines has given
the Company  assurances  that their  reservations  system will be Y2K compliant.
Since airline  reservations  can be made within a year before the actual flight,
American Airlines has until December 31, 1999 to achieve Y2K compliance.  In the
event  American  Airlines fails to achieve  compliance in a timely manner,  this
could result in material adverse  consequences to  Journeycorp's  operations and
would affect its ability to provide  reservations and ticketing for its clients.

Government Regulation

                  Water-Jel's  emergency  first aid products  and  manufacturing
practices are subject to regulation by the Food and Drug Administration  ("FDA")
as well as by similar foreign  authorities.  The Water-Jel Fire Blanket and Burn
Dressing are medical  devices  subject to  regulation  by the FDA. The Company's
generic  creams  and  ointment,  Burn  Jel and  UnBurn  line are  classified  as
over-the-counter drugs. FDA requirements include adherence to good manufacturing
practices,  proper  labeling,  and either premarket  notification  under section
510(k) of the Medical Device  Amendments to the Federal Food, Drug and Cosmetics
Act or  premarket  approval  (depending  on the  category of  product)  prior to
commercial  marketing  in the United  States.  The  Company  is also  subject to
periodic  inspections by the FDA relating to good manufacturing  practices.  The
FDA has the authority to require a suspension of manufacturing  operations if it
finds serious deficiencies. Additional regulation may, in the future, be imposed
by Federal,  state or local authorities,  particularly the FDA. Any new products
will also be subject to review of various  regulatory  authorities  in virtually
every foreign country in which such products are offered for sale. To the extent
that  any  new  products  which  Water-Jel  may  develop  are  deemed  to be new
pharmaceutical or new medical devices,  such products will require FDA and other
regulatory  clearance  and/or  approvals prior to marketing.  Such  governmental
regulation  may prevent or  substantially  delay the  marketing  of any products
developed by Water-Jel,  cause  Water-Jel to undertake  costly  procedures,  and
furnish a competitive advantage to the more substantially  capitalized companies
which compete with Water-Jel. There can assurance that the Company will have the
requisite  financial  resources to complete the regulatory approval process with
respect to any new products which may be developed. 

Product Liability

                  To date,  there  have been no  material  claims on  threatened
claims against the Company by users of its products,  particularly the Water-Jel
products,  based on a failure  to perform  as  specified.  In the event that any
claims for  substantial  amounts were to be asserted  against the Company,  they
could have a materially adverse effect on the Company's  financial condition and
its ability to distribute  its products.  The Company  maintains  $11,000,000 of
general product liability insurance. There is no assurance that this amount will
be sufficient to cover potential  claims or that the present amount of insurance
can be maintained at the present level of cost. 

Dependence on Management

                  The  Company is  significantly  dependent  upon the  continued
availability of Werner Haase, its Co-Chairman and CEO, William Zabit, who became
President


                                       15






upon the  acquisition  of  Zabit,  and  Scott  Mednick,  Co-Chairman  and  Chief
Strategic Officer.  Mr. Haase is under an employment  agreement with the Company
which  terminates  in May 2001,  and both Mr.  Zabit and Mr.  Mednick  are under
employment  agreements  with  the  Company  until  December  2002.  The  loss or
unavailability  of Mr. Haase or Mr.  Zabit or Mr.  Mednick to the Company for an
extended  period of time would have a material  adverse  effect on the Company's
business operations and prospects.  To the extent that Mr. Haase's,  Mr. Zabit's
or Mr.  Mednick's  services  would be unavailable to the Company for any reason,
the Company would be required to procure  other  personnel to manage and operate
the Company.  There can be no assurance that the Company would be able to locate
or employ such qualified personnel on acceptable terms. At the present time, the
Company does not have "key man" life  insurance  covering  any of the  principal
officers of the Company.

Control

                  Werner  Haase,  the Chairman  and CEO of the Company,  and his
wife Nurit Kahane, who is a Senior Vice President of the Company, own together a
total of 2,281,875  shares of the  Company's  Common  Stock,  and Mr. Zabit owns
1,082,591  shares,  which  represent  approximately  25%  of  the  total  shares
outstanding.   Under  Delaware  law,  a  simple  majority  of  stockholders  may
constitute  a quorum  for a meeting  of  stockholders  and may effect any action
requiring a vote of stockholders.  There are no requirements  for  supermajority
votes  on  any  matter,  nor is  there  any  cumulative  voting  for  directors.
Therefore,  Mr.  Haase,  his wife and Mr. Zabit jointly will be in a position to
substantially  influence  the  election  of  directors  and the  conduct  of the
Company's affairs. 


Maintenance Criteria for NASDAQ Securities; Penny Stock Rules

                  The Company's Common Stock is currently quoted on the National
Association of Securities Dealers Automated  Quotation System ("NASDAQ") for the
SmallCap  Market.  To maintain its listing on the NASDAQ  SmallCap  Market,  the
Company must  continue to be registered  under  Section 12(g) of the  Securities
Exchange  Act of 1934 (the  "Exchange  Act") and have  total  assets of at least
$2,000,000, total stockholders' equity of at least $1,000,000, a public float of
at least 100,000 shares with a market value of at least $1,000,000, at least 300
holders,  a minimum bid price of $1.00 per share and at least two market makers.
In addition,  NASDAQ has proposed  increasing the requirements for maintaining a
NASDAQ SmallCap  listing to require either:  (1) net tangible assets of at least
$2,000,000 or $1,000,000,  (2) a market capitalization of $35,000,000 or (3) net
income in at least two of the last three years of $500,000 and a public float of
at least 500,000 shares with a market value of at least $1,000,000.  The Company
currently meets all the proposed  requirements for maintenance of its listing on
the NASDAQ  SmallCap  Market.  There can be no assurance that the Company in the
future will be able to meet the requirements for continued listing on the NASDAQ
SmallCap  Market with respect to the Common Stock.  If the Company's  securities
fail to maintain NASDAQ SmallCap Market listing,  the market value of the Common
Stock likely would decline and purchasers likely would find it more difficult to
dispose  of, or to obtain  accurate  quotations  as to the market  value of, the
Common Stock.

                                       16





                  In addition, if the Company fails the maintain NASDAQ SmallCap
Market listing for its securities, and no other exclusion from the definition of
a "penny stock" under the Exchange Act is available, then any broker engaging in
a  transaction  in the  Company's  securities  would be  required to provide any
customer with a risk disclosure  document,  disclosure of market quotations,  if
any,  disclosure of the compensation of the broker-dealer and its salesperson in
the transaction and monthly account  statements showing the market values of the
Company's securities held in the customer's account. The bid and offer quotation
and compensation information must be provided prior to effecting the transaction
and must be contained on the customer's confirmation.  If brokers become subject
to the "penny  stock"  rules when  engaging  in  transactions  in the  Company's
securities,  they would become less willing to engage in  transactions,  thereby
making it more  difficult  for  purchasers  in this Offering to dispose of their
shares. 

Future Sales of Common Stock

                  As of the current time, there are now 13,608,521 shares of the
Common Stock outstanding.  Approximately 7,142,232 of the outstanding shares are
deemed  to be  "restricted  securities"  ("Restricted  Securities")  within  the
meaning of Rule 144 promulgated  under the Securities Act of 1933 (the "Act") by
virtue of the fact that they are held by  "affiliates"  of the  Company.  Of the
Restricted Securities, approximately 2,560,625 are currently eligible for public
sale in accordance  with Rule 144. Sales made pursuant to Rule 144 could have an
adverse effect on the price of the Common Stock. 


No Dividends

                  The  Company has not paid any cash  dividends  upon its Common
Stock since its inception and, by reason if its present financial status and its
contemplated  financial  requirements,  does  not  anticipate  paying  any  cash
dividends in the foreseeable  future.  It is anticipated that earnings,  if any,
which may be generated from operations will be used to finance the operations of
the Company.

                                 USE OF PROCEEDS

                  Assuming  the  Selling  Shareholders  exercise  all  of  their
options, the total proceeds to the Company would amount to $152,000. Expenses of
the  registration,  including  legal fees,  accounting  fees,  Blue Sky fees and
miscellaneous  expenses are estimated at $18,000, which would leave net proceeds
to the Company from the  exercise of the options of  $134,000.  Any net proceeds
will be added to the working capital of the Company.


                                       17





                              SELLING SHAREHOLDERS

                  The 100,000  shares of Common Stock being  offered  hereby are
held by three  selling  shareholders.  A Selling  Shareholder  listed  below may
choose  not to sell all of the  shares of  Common  Stock  owned by such  Selling
Shareholder in this offering. The chart below sets forth the number of shares to
be offered for sale by each such  Selling  Shareholder,  which  information  was
furnished to the Company by each such Selling  Shareholder.  The chart also sets
forth  the  amount  and  percentage  of Common  Stock to be owned by each  after
completion of the  offering,  assuming the sale of all such shares owned by such
Selling   Shareholder.   Unless  otherwise   indicated,   none  of  the  Selling
Shareholders  listed has held any  position  with the  Company in the last three
years. The Selling Shareholders have not entered into any arrangements regarding
the sale of their  shares and have  informed  the  Company  that any shares sold
would be sold in normal brokerage transactions.


                        Securities Owned    Securities       Securities to Be
Name                     before Offering    To Be Sold     Owned after Offering
- ----                     ---------------    ----------     --------------------
Robert Daniels (1)          70,000 (2)        70,000              -0-
Gerald J. Resnick (3)       10,000 (2)        10,000              -0-
Neil H. Deutsch (3)         20,000 (2)        20,000              -0-
- --------------
         (1) Mr.  Daniels  was  employed  by the  Company as an  Executive  Vice
President in charge of Sales and Marketing. He left the Company on June 2, 1995.
In connection with the settlement of litigation involving a claim by the Company
that Mr. Daniels violated an  anti-competition  agreement and a counter-claim by
Mr. Daniels against the Company, the Company agreed to settle all claims for the
sum of  $75,000  and the  reinstatement  and  registration  of  100,000  options
previously granted to Mr. Daniels. Mr. Daniels, with the consent of the Company,
assigned 30,000 options to the attorneys who represented  him, the other Selling
Shareholders,  as payment of legal fees.  All of the options are  exercisable at
$1.52 per share.  A settlement  agreement  was entered into on June 11, 1998, at
which time the closing  price of the  Company's  Common stock as reported on the
NASDAQ SmallCap Market was $4.25.

         (2)  The  above  figures  represent  options  granted  to  the  Selling
Shareholders.

         (3) These Selling  Shareholders  are the attorneys who  represented Mr.
Daniels in connection  with the  litigation  referred to in footnote 1 above and
accepted an  assignment  of options  from Mr.  Daniels in payment of their legal
fees.

                              PLAN OF DISTRIBUTION

                  The shares are being  offered for the  respective  accounts of
the Selling Shareholders.  The Company will not receive any of the proceeds from
the sale of securities. The Company will, however, receive the exercise price of
$1.52 per share as set forth in the options for those  options  exercised by the
Selling Shareholders.

                  The sale for the  shares by the  Selling  Shareholders  may be
effected from time to time in  transactions on the NASDAQ  SmallCap  Market,  at
fixed prices or negotiated  prices relating to the then prevailing market price.
The Selling Shareholders may effect such transaction by selling

                                       18





the Securities to or through registered broker-dealers,  and such broker-dealers
may  receive  compensation  in the form of  discounts  or  commissions  from the
Selling  Shareholders  and for the  purchases of the  Securities  for which such
broker-dealers may act as agent or to whom they may sell as principal or both.
                  The Selling  Shareholders  and any  broker-dealers  who act in
connection  with  the  Sale of the  securities  hereunder  may be  deemed  to be
"underwriters"  within the meaning of Section 2 (11) or the  Securities  Act and
any commissions  received by them and any profit received by them on any sale of
the Securities as principal might be deemed to represent  underwriting discounts
or commissions under the Securities Act.

                                  LEGAL MATTERS

                  Certain  legal  matters in  connection  with this offering are
being  passed  upon for the  Company by  McLaughlin  & Stern,  LLP,  260 Madison
Avenue, New York, New York 10016.

                                     EXPERTS

                  The financial  statements of X-ceed, Inc. for the fiscal years
ended  August  31,  1997,  1996 and 1995,  incorporated  by  reference  from the
Company's annual reports on Form 10- KSB, have been examined by Holtz Rubenstein
& Co. LLP, independent certified public accountants,  as stated in their report,
and are  included  in  reliance  upon the  report  of such  firm and upon  their
authority as experts on accounting and auditing.


                INCORPORATION OF CERTAIN INFORMATION BY REFERENCE


                  The  following  documents,  which  have  been  filed  with the
Commission by the , are incorporated herein by reference and made a part hereof.
The Commission file number for documents which are  incorporated by reference is
0-13049.


                  1.       The Company's  latest  Annual  Reports on Form 10-KSB
                           for the fiscal years ended August 31, 1996 and August
                           31,  1997  filed  pursuant  to  Section  13(a) of the
                           Exchange Act which contain  financial  statements for
                           the  Company's  latest  fiscal year (August 31, 1997)
                           for which a Form  10-KSB  was  required  to have been
                           filed and for the Company's  fiscal year ended August
                           31, 1996.

                  2.       The Company's  quarterly reports on Form 10-Q for the
                           three months ended  November 30, 1997,  for the three
                           and six months  ended  February  28, 1998 and for the
                           three and nine months ended May 31, 1998.

                  3.       The Company's Current Report on Form 8-K dated May 7,
                           1998 and amendments thereto.


                  4.       The Company's  Current  Report on Form 8-K,  together
                           with  exhibits,  dated August 13, 1998 and filed with
                           the Commission on August 14, 1998.


                                       19






                  5.       The Company's  Current  Report on Form 8-K,  together
                           with  exhibits,  dated  September  17, 1998 and filed
                           with the Commission on September 17, 1998.


                  6.       The Company's Current Report on Form 8-K/A, together 
                           with audited financial statements for Reset, Inc. and
                           Mercury Seven, Inc. and unaudited pro forma combined 
                           financial statements, dated November 10, 1998 and 
                           filed with the Commission on November 10, 1998.

                  7.       The section  entitled  "Description of Securities" in
                           the  Company's  Registration  Statement  on Form  S-1
                           (Registration  No.  33-23910)  declared  effective on
                           October 31, 1988.


                  In addition,  all documents  filed by the Company  pursuant to
Section 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the termination
of the offering of the Shares shall be deemed to be incorporated by reference in
this  Prospectus  and to be a part  hereof  from  the  date  of  filing  of such
documents. Any statement modified in a document incorporated by reference herein
shall be deemed to be contained  herein or superseded for purposes hereof to the
extent that a statement  contained herein (or in any subsequently filed document
which is also  incorporated  by reference  herein)  modifies or supersedes  such
statement.  Any  statement  so  modified  or  superseded  shall not be deemed to
constitute a part hereof except as so modified or superseded.

                  A copy of the  documents  incorporated  by  reference  in this
Prospectus  (not including  exhibits to the  incorporated  documents  unless the
documents specifically  incorporate the exhibits by reference) will be furnished
without  charge to each  person,  including  any  beneficial  owner to whom this
prospectus is delivered, on the written or oral request of such person. All such
requests should be addressed to: Alex Alaminos,  Investor  Relations,  Water-Jel
Technologies, 243 Veterans Blvd., Carlstadt, NJ 07072.

                      DISCLOSURE OF COMMISSION POSITION ON
                 INDEMNIFICATION FOR SECURITIES ACT LIABILITIES

                  The Company's Certificate of Incorporation permits the Company
to indemnify  directors,  officers,  employees and agents to the fullest  extent
permissible under the Delaware General Corporation Law.

                  Insofar  as  indemnification  for  liabilities  arising  under
Securities Act of 1933 may be permitted to directors,  officers and  controlling
persons of the  Company  pursuant  to any  charter  provision,  by-law  contract
arrangements  statute,  or  otherwise,  the Company has been advised that in the
opinion of the  Securities  and  Exchange  Commission  such  indemnification  is
against  public  policy as expressed  in the  Securities  Act and is  therefore,
unenforceable.

                                       20







- ------------------------------------------   -----------------------------------


No dealer,  salesman  or any other  person
has   been    authorized   to   give   any
information or to make any representations
other   than  those   contained   in  this
Prospectus   in   connection   with   this
offering  and,  if  given  or  made,  such
information or representations must not be
relied upon as having been  authorized  by
the  Company  or  the  Underwriters.  This
Prospectus does not constitute an offer to
sell, or the  solicitation  of an offer to
buy, any of the securities  offered hereby
in any  jurisdiction to any person to whom              100,000 Shares
it is  unlawful  to  make  such  offer  or              of Common Stock
solicitation in such jurisdiction. Neither             ($.01 Par Value)
the  delivery of this  Prospectus  nor any
sale  made  hereunder  shall,   under  any
circumstances, create any implication that
the   information   contained   herein  is
correct as of any time  subsequent  to the                X-ceed, Inc.
date  hereof  or that  there  has  been no
change in the affairs of the Company since
such date.

       --------------------------

          TABLE OF CONTENTS



                                     PAGE 
AVAILABLE INFORMATION....................3        __________________________
FORWARD-LOOKING STATEMENTS...............4
PROSPECTUS SUMMARY.......................4                PROSPECTUS
SELECTED FINANCIAL DATA..................8        __________________________
THE OFFERING.............................9
RISK FACTORS............................10 
USE OF PROCEEDS.........................18
SELLING SHAREHOLDERS....................18
PLAN OF DISTRIBUTION....................19
LEGAL MATTERS...........................20
EXPERTS.................................20
INCORPORATION OF CERTAIN INFORMATION
     BY REFERENCE.......................20
DISCLOSURE OF COMMISSION POSITION ON
     INDEMNIFICATION FOR SECURITIES ACT
     LIABILITIES........................21



       --------------------------
Until ________________,  1998, all dealers
effecting transactions in these registered
securities,  whether or not  participating
in this  distribution,  may be required to
deliver a Prospectus.  This is in addition            November ____, 1998
to the  obligation of dealers to deliver a
Prospectus when acting as Underwriters.


- ------------------------------------------   -----------------------------------




                                     PART II

                     INFORMATION NOT REQUIRED IN PROSPECTUS

ITEM 14.  Other Expenses of Issuance and Distribution

                  The expenses in connection with the issuance and  distribution
of the securities being registered hereunder are estimate as follows:

                  Blue Sky qualification fees and expenses..............$  2,000
                  Legal fees and expenses..................................8,500
                  Accountant's fees and expenses...........................6,000
                  Miscellaneous........................................    1,500
                  Total                                                  $18,000

ITEM 15.  Indemnification of Directors and Officers

                  Pursuant  to Section  145 of the  General  Corporation  Law of
Delaware  (the  "Delaware   Corporation  Law"),   Article  7  of  the  Company's
Certificate of  Incorporation,  a copy of which is filed as Exhibit 3(c) to this
Registration  Statement,  provides  that the  Company  shall  indemnify,  to the
fullest  extent  permitted  by Section 145 of the Delaware  Corporation  Law, as
amended from time to time,  each person that such section grants the Corporation
the power to indemnify.  Section 145 of the Delaware Corporation Law permits the
Company to indemnify any person in connection  with the defense or settlement of
any  threatened,  pending or  completed  legal  proceeding  (other  than a legal
proceeding  by or in the right of the  Company) by reason of the fact that he is
or was a director  or officer of the  Company or is or was a director or officer
of the Company  serving at the  request of the  Company as a director,  officer,
employee  or agent  of  another  corporation,  partnership  or other  enterprise
against expenses (including attorneys' fees), judgments,  fines and amounts paid
in settlement actually and reasonably incurred in connection with the defense or
settlement  of such legal  proceeding  if he acted in good faith and in a manner
that he reasonably believes to be in or not opposed to the best interests of the
Company,  and, with respect to any criminal  action of proceeding,  if he had no
reasonable  cause to  believe  that  his  conduct  was  unlawful.  It the  legal
proceeding,  however,  is by or in the right of the  Company,  the  director  or
officer may be indemnified by the Company against expense (including  attorneys'
fees)  actually  and  reasonably  incurred  in  connection  with the  defense or
settlement of such legal proceeding if he acted in good faith and in a manner he
reasonably believed to be in or not opposed to the best interests of the Company
and except  that he may not be  indemnified  in  respect of any claim,  issue or
matter as to which he shall  have  been  adjudged  to be  liable to the  Company
unless a court determines otherwise.

                  Pursuant to Section 102(b)(7) of the Delaware Corporation Law,
Article 7 of the Certificate of Incorporation of the Company, a copy of which is
filed as Exhibit 3(c) to this Registration Statement,  provides that no director
of the Company shall be personally liable to the Company or its stockholders for
monetary  damages for any breach of his fiduciary duty as a director;  provided,
however, that such clause shall not apply to any liability of a director (i) for
breach of his duty of loyalty to the Company or its stockholders,  (ii) for acts
or omissions that are not in good faith

                                       22



or involve intentional misconduct or a knowing violation of the law, (iii) under
Section 174 of the Delaware  Corporation  Law, or (iv) for any transaction  from
which the director derived an improper personal benefit. The aforesaid provision
also  eliminates  the  liability  of any  stockholder  for  managerial  acts  or
omissions,  pursuant to Section 350 of the Delaware Corporation Law or any other
provision of Delaware law, to the same extent that such liability is limited for
a director.

                  The  Company  maintains   directors  and  officers   liability
insurance.

ITEM 16.  Exhibits

2(d)  Agreement and Plan of Merger and Reorganization between X-ceed, Inc. and
      X-ceed Acquisitions, Inc. and Reset, Inc. and the Shareholders of 
      Reset (1)
2(e)  Agreement and Plan of Merger by and among X-ceed, Inc., X-ceed Merger 
      Inc., Mercury Seven, Inc. and the Shareholders of Mercury Seven, Inc. (2)
2(g)  Agreement and Plan of Merger by and among X-ceed, Inc., Zabit and 
      Associates, Inc. and the Shareholders named therein (2)
2(h)  Certificate of Merger of Zabit and Associates, Inc. into X-ceed, Inc. (2)
3(c)  Certificate of Incorporation of X-ceed,  Inc. (3)
4(a)  Form of Common Stock (4)
5     Opinion of McLaughlin & Stern, LLP*
10(j) Stock Purchase Agreement among X-ceed, Inc., William Zabit and Joyce
      Wesolowski (2)
10(k) Purchase Agreement by and among X-ceed, Inc., William Zabit and Joyce M.
      Wesolowski (2)
10(l) Employment Agreement of Scott Mednick*
10(m) Employment Agreement of William Zabit*
   
23(a) Consent of Holtz Rubenstein & Co. LLP dated November 19, 1998*
    
23(b) Consent of McLaughlin & Stern, LLP (included in Exhibit 5)
- --------------
         *     Filed herewith.

         (1) Incorporated by reference from the Company's Current Report on Form
8-K filed with the Commission on August 14, 1998.

         (2) Incorporated by reference from the Company's Current Report on Form
8-K filed with the Commission on September 17, 1998.

         (3) Incorporated by reference from the Company's Current Report on Form
8-K filed with the Commission on February 27, 1998.

         (4) Incorporated by reference from the Company's Registration Statement
on Form S-18 filed with the  Commission on April 12, 1984,  Commission  File No.
2-90512-NY.


ITEM 17.  Undertakings

                  The undersigned Company hereby undertakes:

                  (1) To file,  during any  period in which  offers or sales are
being made, a  post-effective  amendment to this  Registration  Statement (i) to
include any prospectus required by Section 10(a)

                                       23





of the Act and (ii) to reflect  in the  prospectus  any facts or events  arising
after the  effective  date of the  Registration  Statement  (or the most  recent
post-effective  amendment  thereof)  which  individually  or  in  the  aggregate
represents a fundamental change in the information in the Registration Statement
and (iii) to  include  any  material  information  with  respect  to the plan of
distribution  not  previously  disclosed  in the  Registration  Statement or any
material change to such  information in the  Registration  Statement;  provided,
however,  that if the  information  required to be included in a  post-effective
amendment is included in periodic  reports filed or furnished to the  Commission
by the Company pursuant to section 13 or Section 15(d) of the Exchange Act, then
the Company shall not be required to file a post-effective amendment.

                  (2) That, for the purpose of determining  any liability  under
the Securities Act of 1933, each such  post-effective  amendment shall be deemed
to be a new registration  statement  relating to the securities  offered therein
and the  offering  of such  securities  at that  time  shall be deemed to be the
initial bona fide offering thereof.

                  (3) To remove from  registration by means of a  post-effective
amendment  any of the  securities  being  registered  which remain unsold at the
termination of the offering.

                  (4) That for purposes of determining  any liability  under the
Securities  Act of 1933,  each filing of  Company's  annual  report  pursuant to
Section  13(a) or 15(d)  of the  Securities  Exchange  Act of 1934  (and,  where
applicable,  each filing of an employee benefit plan's annual report pursuant to
Section 15(d) of the Securities  Exchange Act of 1934) that is  incorporated  by
reference in the Registration Statement shall be deemed to be a new registration
statement relating to the securities  offered therein,  and the offering of such
securities  at that time shall be deemed to be the  initial  bona fide  offering
thereof.

                  (5) In the event  acceleration is requested by the Company and
insofar as indemnification  for liabilities  arising under the Securities Act of
1933 may be permitted to  directors,  officers  and  controlling  persons of the
registrant pursuant to the foregoing  provisions,  or otherwise,  the registrant
has been advised that in the opinion of the Securities  and Exchange  Commission
such  indemnification  is against  public policy as expressed in the Act and is,
therefore,  unenforceable. In the event that a claim for indemnification against
such liabilities  (other than the payment by the registrant of expenses incurred
or paid by a director,  officer or  controlling  person of the registrant in the
successful  defense of any  action,  suit or  proceeding)  is  asserted  by such
director,  officer or controlling person in connection with the securities being
registered, the registrant will, unless in the opinion of its counsel the matter
has been  settled by  controlling  precedent,  submit to a court of  appropriate
jurisdiction the question whether such  indemnification  by it is against public
policy as expressed in the Act and will be governed by the final adjudication of
such issue.

                                       24




                                   SIGNATURES

   
                  Pursuant to the  requirements  of the  Securities Act of 1933,
the Registrant,  X-ceed,  Inc., has duly caused this  Registration  Statement on
Form  S-3/A to be  signed  on its  behalf  by the  undersigned,  thereunto  duly
authorized, in New York, New York on November 19, 1998.
    

                                     X-CEED, INC.

                                     By: /s/ Werner G. Haase
                                         Werner G. Haase

                                         Chief Executive Officer



                                POWER OF ATTORNEY

                  KNOW ALL MEN BY THESE  PRESENTS,  that each of the undersigned
hereby   constitutes   and  appoints   Werner  G.  Haase  his  true  and  lawful
attorney-in-fact  and agent, with full power of substitution and resubstitution,
for him and in his name, place and stead, in any and all capacities, to sign any
or  all  pre-effective  and   post-effective   amendments  to  the  Registration
Statement,  and to file the same, with all exhibits thereto, and other documents
in connection therewith,  with the Securities and Exchange Commission,  granting
unto said  attorney-in-fact and agent full power and authority to do and perform
each and every act and thing requisite and necessary to be done in and about the
premises,  as  fully  to all  intents  and  purposes  as he might or could do in
person,  hereby  ratifying and  confirming  all that said  attorney-in-fact  and
agent, or his substitutes, may lawfully do or cause to be done by virtue hereof.

                  Pursuant to the  requirements  of the  Securities Act of 1933,
this  Registration  Statement has been signed below by the following  persons in
the capacities and on the dates indicated.


   
          Signature                             Title                     Date
/s/ Werner G. Haase                             Chief Executive         11/19/98
Werner G. Haase                                 Officer, Principal

/s/ Norman Doctoroff,                           Director                11/19/98
    by Werner G. Haase, attorney-in-fact
Norman Doctoroff

/s/ John Bermingham                             Director                11/19/98
    by Werner G. Haase, attorney-in-fact
John Bermingham
    

                                       25